Deal struck for treatment of Periodic Fever Syndromes

Author: Jo Carlowe

Like Comment

NHS England is to fund a life-changing treatment for people with Periodic fever syndromes (PFS).

On World Rare Diseases Day, which took place this weekend, the NHS confirmed a deal has been struck for the drug – canakinumab – which modifies the immune system, turning off the inflammation process, significantly reducing the number of ‘flares’ children and adults experience.

The deal with a global pharmaceutical firm has been agreed after negotiations led by the NHS, as part of a major programme to ramp up access to innovative treatments, while freeing up funding for frontline patient care through smarter procurement.

The agreement brings into the NHS a more effective, convenient drug with fewer side effects than existing treatments, and follows contracts agreed in recent months which introduced new drugs for restoring sight and cystic fibrosis.

Commenting, Sir Simon Stevens, chief executive of NHS England, said: “Some illnesses affect a small number in a big way, which is why the NHS is increasingly bringing innovative, specialised and targeted treatments to people who need them.

“This latest new treatment has the potential to significantly improve the lives of children who bear the burden of bouts of crippling pain which blights lives and puts strain on families. It’s the latest in a line of major deals NHS England has successfully negotiated, which show that when drug companies play ball with the NHS, taxpayers get a fair deal and patients get cutting-edge treatments.”

There are around 168 patients in England with these diseases, both children and adults, and around 80% of these would be prescribed canakinumab.

The discounted price of canakinumab, developed by Novartis, is commercial in confidence.

Patients with three different types of periodic fever conditions will be eligible for treatment: familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and tumour necrosis factor receptor–associated periodic syndrome (TRAPS).

Symptoms include high temperature, severe fatigue, severe abdominal, chest or joint pains, headaches, rashes and mouth ulcers, and flares can last several days or even weeks, with long-term risk of organ failure or even death if not treated.

Current treatments which include anti-inflammatory and immune-suppressing drugs such as high-dose steroids and ibuprofen are not always effective, and some may cause side effects including weight gain, skin and bone thinning and susceptibility to diabetes and infections.

Another treatment option is Anakinra which does not work for everyone and is taken daily via an injection which can be unpleasant for patients. Canakinumab is only injected every 8-12 weeks and is transformative – allowing patients to live more normal lives.


Editorial team, Wilmington Healthcare

OnMedica provides high-quality, easy to digest content and CPD for UK-based GPs and clinicians. Our team of expert editors and clinicians develops content across a wide range of topics in a variety of formats—expert articles, bitesize news and quizzes, courses, videos, and more. You can explore OnMedica via the homepage, drop down menu or by typing your topic of choice in the search bar. Why not find out how OnMedica can help you to keep up to date quickly and easily?
4674 Contributions
2 Following